Consensus Corbus Pharmaceuticals Holdings, Inc.

Stocks

CRBP

US21833P3010

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2026-08-14 EDT			5-day change	1st Jan Change
10.09 ^USD	+0.10%		-0.79%	+23.96%

08-13	Mizuho Adjusts PT on Corbus Pharmaceuticals to $33 From $34, Keeps Outperform Rating	MT
08-07	Oppenheimer Adjusts PT on Corbus Pharmaceuticals to $48 From $52, Maintains Outperform Rating	MT

Evolution of the Average Target: Corbus Pharmaceuticals Holdings, Inc.

Evolution of the Target Price: Corbus Pharmaceuticals Holdings, Inc.

Changes in Analyst Recommendations: Corbus Pharmaceuticals Holdings, Inc.

26ea757.Zuj0J-NMG3Ga9ak1yGXpzv4Hp8mB2-aJDv543pkpOwY.K623Vq8KbD-ruuBFshK_t41syafxmpHII7watfBsUlZTgcB91g4vOd2v7A~94d3b9098dc06fe1873e705339a10c7a

Analysts' recommendations: Corbus Pharmaceuticals Holdings, Inc.

08-13	Mizuho Adjusts PT on Corbus Pharmaceuticals to $33 From $34, Keeps Outperform Rating	MT
08-07	Oppenheimer Adjusts PT on Corbus Pharmaceuticals to $48 From $52, Maintains Outperform Rating	MT
06-23	Mizuho Securities Cuts Price Target on Corbus Pharmaceuticals to $34 From $44, Maintains Outperform Rating	MT
06-17	Oppenheimer Adjusts PT on Corbus Pharmaceuticals to $52 From $54, Maintains Outperform Rating	MT
05-22	Mizuho Adjusts Price Target on Corbus Pharmaceuticals to $44 From $40, Maintains Outperform Rating	MT
05-13	Oppenheimer Adjusts Price Target on Corbus Pharmaceuticals to $54 From $57, Maintains Outperform Rating	MT
04-29	Mizuho Keept Price Target on Corbus Pharmaceuticals to $40, Maintains Outperform Rating	MT
04-29	Mizuho Adjusts Price Target on Corbus Pharmaceuticals to $40 From $39, Maintains Outperform Rating	MT
04-29	Guggenheim Initiates Corbus Pharmaceuticals at Buy With $45 Price Target	MT
04-02	Mizuho Lifts Price Target on Corbus Pharmaceuticals Holdings to $40 From $39, Keeps Outperform Rating	MT
11-13	RBC Trims Price Target on Corbus Pharmaceuticals Holdings to $53 From $55, Keeps Outperform, Speculative Risk	MT
25-10-20	Wedbush Raises Price Target on Corbus Pharmaceuticals Holdings to $38 From $31, Keeps Outperform Rating	MT
25-10-18	Corbus Pharmaceuticals Holdings, Inc. Presents CRB-701 Robust Clinical Responses in HNSCC and Cervical Cancers at ESMO25	CI
25-10-14	Corbus Pharmaceuticals Holdings Inc. to Present CRB-701 Phase 1/2 Data At ESMO 2025	CI
25-05-20	Mizuho Securities Adjusts Corbus Pharmaceuticals Price Target to $32 From $42, Maintains Outperform Rating	MT
25-05-20	Mizuho Cuts Price Target on Corbus Pharmaceuticals Holdings to $32 From $42, Keeps Outperform Rating	MT
25-05-07	RBC Cuts Price Target on Corbus Pharmaceuticals Holdings to $58 From $65, Keeps Outperform, Speculative Risk	MT
25-02-28	William Blair Initiates Corbus Pharmaceuticals at Outperform	MT
24-09-24	Mizuho Cuts Price Target on Corbus Pharmaceuticals Holdings to $42 From $74, Keeps Outperform Rating	MT
24-09-23	B. Riley Cuts Price Target on Corbus Pharmaceuticals Holdings to $40 From $85, Keeps Buy Rating	MT
24-09-20	Top Midday Decliners	MT
24-09-20	Wedbush Cuts Corbus Pharmaceuticals Price Target to $51 From $85, Maintains Outperform Rating; Shares Tumble	MT
24-08-27	Mizuho Initiates Corbus Pharmaceuticals at Outperform With $74 Price Target	MT
24-08-07	Oppenheimer Adjusts Corbus Pharmaceuticals Price Target to $88 From $80, Maintains Outperform Rating	MT
24-07-30	Wedbush Initiates Corbus Pharmaceuticals at Outperform With $85 Price Target	MT

More recommendations

Sector Comparison:

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
CORBUS PHARMACEUTICALS HOLDINGS, INC.			+242.17%
WUXI APPTEC CO., LTD.			+14.63%
ARGENX SE	-	-	+45.47%
INSMED INCORPORATED			+61.67%
WUXI BIOLOGICS (CAYMAN) INC.			+5.3%
BIONTECH SE			+29.48%
PHARMAESSENTIA CORPORATION			-18.91%
GENMAB A/S			+18.92%
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.			+9.52%
EXELIXIS, INC.			+3.31%
Average			+41.16%
Weighted average by Cap.			+23.26%